.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
STEP 2 studied semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. At 68 weeks, semaglutide 2.4 mg produced substantially greater weight loss than placebo and greater loss than the 1.0-mg diabetes dose. Glycemic measures and several cardiometabolic outcomes also improved. The study is useful for physicians managing the common triad of diabetes, obesity and cardiovascular risk. It demonstrates that treatment intensity and therapeutic goals can be tailored to the patient's phenotype rather than treating HbA1c in isolation. Gastrointestinal symptoms were common, and long-term continuation is important because obesity is a chronic disease and weight regain can follow treatment withdrawal. In practice, semaglutide should be introduced with clear expectations about dose escalation, nutrition, physical activity and monitoring. The broader lesson is that modern diabetes therapy can simultaneously address glycemic control and excess adiposity, which may improve the overall risk profile of appropriately selected patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
STEP 2 studied semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. At 68 weeks, semaglutide 2.4 mg produced substantially greater weight loss than placebo and greater loss than the 1.0-mg diabetes dose. Glycemic measures and several cardiometabolic outcomes also improved. The study is useful for physicians managing the common triad of diabetes, obesity and cardiovascular risk. It demonstrates that treatment intensity and therapeutic goals can be tailored to the patient's phenotype rather than treating HbA1c in isolation. Gastrointestinal symptoms were common, and long-term continuation is important because obesity is a chronic disease and weight regain can follow treatment withdrawal. In practice, semaglutide should be introduced with clear expectations about dose escalation, nutrition, physical activity and monitoring. The broader lesson is that modern diabetes therapy can simultaneously address glycemic control and excess adiposity, which may improve the overall risk profile of appropriately selected patients.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
